Page 9 - Eva Kalias News Today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Pratteln, Switzerland, May 4, 2021 – Santhera ...

Santhera Pharmaceuticals Holding AG: Santhera Announces Settlement of Exchange Offer and Issuance of New Senior Unsecured Convertible Bonds due 2024 Pratteln, Switzerland, s the settlement of the e . Santhera Pharmaceuticals Holding AG is settling today its offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the 2017/22 Bonds) on the terms set out in the Notice of Repurchase Offer dated March 25, 2021 (the Exchange Offer). Upon settlement, 2017/22 Bonds in the a...

More from AP

By Notice of Repurchase Offer dated March 25, 2021 (the Notice), Santhera Pharmaceuticals Holding AG announced an offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the 2017/22 Bonds) on the terms set out in the Notice (the Exchange Offer). The Exchange Offer was accepted by bondholders with respect to 2017/22 Bonds with an aggregate principal amount of CHF 44,845,000, corresponding to 74.7% of all 2017/22 Bonds in circulation. S ettlement Santhera has decide...

By Notice of Repurchase Offer dated March 25, 2021 (the Notice), Santhera Pharmaceuticals Holding AG announced an offer to exchange its outstanding CHF 60 million 5% Convertible Bonds due 2022 (the 2017/22 Bonds) on the terms set out in the Notice (the Exchange Offer). The Exchange Offer was accepted by bondholders with respect to 2017/22 Bonds with an aggregate principal amount of CHF 44,845,000, corresponding to 74.7% of all 2017/22 Bonds in circulation. S ettlement Santhera has decide...

Santhera Pharmaceuticals Holding AG: Santhera gibt den Vollzug des Umtauschangebots für die Wandelanleihe per 4. Mai 2021 bekannt Pratteln, Schweiz, 3. März 2021 angekündigte Umtauschangebot für die CHF 60 Millionen Wandelanleihe am 4. Mai 2021 vollzogen wird. Mit dem Rückkaufsinserat vom 25. März 2021 (das Rückkaufsinserat) veröffentlichte Santhera Pharmaceuticals Holding AG ein Angebot zum Umtausch der ausstehenden CHF 60 Millionen 5%-Wandelanleihe mit Fälligkeit 2022 (die 2017/22 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Santhera Completes Capital Increases for Financing Arrangements Santhera Pharmaceuticals Holding AGApril 30, 2021 GMT Pratteln, Switzerland, April 30, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 2,312,000 treasury shares. On April 30, 2021, Santhera completed the ordinary capital increase resolved on March 18, 2021, by issuing 312,000 new treasury shares for purposes...

Santhera Pharmaceuticals Holding AG: Santhera Completes Capital Increases for Financing Arrangements 2, shares. On April 30, 2021, Santhera completed the ordinary capital increase resolved on March 18, 2021, by issuing 312,000 new treasury shares for purposes of the planned restructuring of the CHF 60 million convertible bond 2017-2022 (ISIN CH0353955195) and potentially for other purposes. At the same time, 2,000,000 shares were issued out of the existing authorized capital as treasury shares...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

Santhera Pharmaceuticals Holding AG: Santhera Reports 2020 Annual Results 4 this statement. CHF 67.7 20 as the basis for future growth S Pratteln, Switzerland, Company 20 lead uchenne muscular dystrophy (D . "Santhera started 2021 with the strong foundation of a refreshed clinical and operational strategy focused on vamorolone, which we believe can provide significant value to patients, caregivers, and ultimately shareholders. It represents the key foundation for the future of Santhera, wh...